Disease-specific alterations were useful for targeted therapies as for patient 50,29 who had a pilocytic astrocytoma diagnosis and who received a targeted treatment with a MEK inhibitor (trametinib dimethyl sulfoxide) according to the molecular profiling analysis, which uncovered a mutation in NF1 (N1465S; 4763), a negative regulator of the Ras signal transduction pathway. This evidence concerns the gene MAP2K7 and pilocytic astrocytoma.